肥胖2型糖尿病患者血清MCP-1水平变化及其与AS的关系研究

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo explore change of serum monocyte chemoattractant protein-1 (MCP-1)level in obese patients with type 2 diabetes mellitus(T2DM)and its relationship with atherosclerosis(AS).MethodsFrom January 2015 to August 2016,30 patients newly diagnosed as T2DM in obesity(T2DM obesity group,BMI≥28.0 kg/m2),30 patients in moderate size(T2DM non-obesity group,18.5 kg/m2≤BMI＜24.0 kg/m2),and 30 healthy participants after physical examinations (NC group,18.5 kg/m2≤BMI＜24.0 kg/m2).The levels of serum MCP-1 and other experimental indexes in empty stomach in each group were tested.Homeostasis model assessment of insulin resistance(HOMA-IR),insulin sensitivity index(ISI), and atherogenic index of plasma(AIP)were calculated.ResultsThe①levels of serum MCP-1 in the T2DM obesity group and T2DM non-obesity group were both much higher than that in the NC group.Serum MCP-1 in the T2DM obesity group was high than that in the T2DM non-obesity group with a statistical difference(P＜0.05).②Correlation analysis indicated that serum MCP-1 had positive relationships with body mass index(BMI),triglyceride(TG),total cholesterol(TC), fasting plasma glucose(FPG),HOMA-IR and AIP(P＜0.05).Serum MCP-1 was in a negative relationship with high-density lipoprotein cholesterol(HDL-C)or ISI(P＜0.05).③With regard to multiple stepwise regression analysis,it was indicated BMI,TC,FPG,and AIP were all enrolled into the regression equation based on the dependent variable of MCP-1 (P＜0.05).ConclusionMCP-1 is one of the key factors to promote occurrence and development of AS and IR.By testing the level of MCP-1 and implementing the corresponding intervention,it can relieve the degree of IR and AS.It is expected that MCP-1 will become a new cutting target for the treatment of macrovascular and microvascular complications in T2DM.

Key words： Monocyte chemoattractant protein-1 Obesity Type 2 diabetes mellitus Insulin resistance Atherosclerosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Hui-hui
	YAN Xiao-guang
	YU Xiu-nan
	ZHANG Hai-jun
	SUN Zhe

Cite this article:

WANG Hui-hui,YAN Xiao-guang,YU Xiu-nan, et al. Research on change of serum MCP-1 level in obese patients with type 2 diabetes and its relationship with AS[J]. 中国当代医药, 2017, 24(2): 39-41.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I2/39

[1]	Nishoka H，Kanauchi M，Dohi K.Role of monocyte chemotactic peptide 1 in diabetic nephropathy[J].Nephron，2001， 88（2）：189-190.
[4]	黄艳，赵亚萍，王加林.肥胖相关胰岛素抵抗分子机制的研究进展[J].东南国防医药，2010，12（6）：526-529.
[5]	张如卉，李志棵，付强，等.冠心病患者血浆中单核细胞趋化蛋白-1的意义[J].临床心血病杂志，2012，28（9）：367-370.
[7]	史兆坤，丁鹏，孙杰，等.单核细胞趋化蛋白1趋化巨噬细胞迁移与侵袭的体外实验研究[J].昆明医科大学学报，2014，35（4）：41-45.
[2]	Chen S，Hong SW，Iglesias-de la Cruz MC，et al.The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy[J].Ren Fail，2001，23（3-4）：471-481.
[3]	Deshmane SL，Kremley S，Amini S，et al.Monocyte chemoattractant protein-1（MCP-1）：an overview[J].J Interferon Cytokine Res，2009，29（6）：313-326.
[6]	Satiroglu O，Uydu HA，Demir A，et al.Association between plasma monocyte chemoattractant protein-1 levels and the extent of atherosclerotic peripheral artery disease[J].Tohoku J Exp Med，2011，224（4）：301-306.
[8]	Majmudar MD，Keliher EJ，Heidt T，et al.Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice[J].Circulation，2013，127（20）：2038-2046.
[9]	Morita T，Okada M，Yamawaki H.Mechanisms underlying a decrease in KCl-induced contraction after long-term serum-free organ culture of rat isolated mesenteric artery[J]. J Vet Med Sci，2014，76（7）：963-969.
[10]	Woollard KJ，Geissmann F.Monocytes in atherosclerosis：subsets and functions[J].Nat Rev Cardiol，2010，7（2）：77-86.
[11]	Uchida E，Anan F，Masaki T，et al.Monocyte chemoattractant protein-1 is associated with silent cerebral infarction in patients on haemodialysis[J].Intern Med J，2012，42（1）：29-34.
[12]	倪正平，张建，巴荣，等.巨噬细胞移动抑制因子对2型糖尿病患者血管病变的影响[J].江苏医药，2012，38（3）：275-277.
[13]	Mathiesen EB，Johnsen SH，Wilsgaard T，et al.Carotid plaque area and intima-media thickness in prediction of first-ever ischemic stroke：a 10-year follow-up of 6584 men and women：the Tromsø Study[J].Stroke，2011，42（4）：972-978.
[14]	Takayama S，Kawamoto R，Kusunoki T，et al.Uric acid is an independent risk factor for carotid atherosclerosis in a Japanese elderly population without metabolic syndrome[J]. Cardiovasc Diabetol，2012，11：2.
[15]	Baldwin W，McRae S，Marek G，et al.Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome[J].Diabetes，2011，60（4）：1258-1269.